About regencell bioscience holdings ltd - RGC
Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.
RGC At a Glance
Regencell Bioscience Holdings Ltd.
Chinachem Leighton Plaza
Hong Kong,
| Phone | 852-2155-0823 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -3,584,213.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
RGC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1,733.47 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2,493.667 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
RGC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -358,421.30 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RGC Liquidity
| Current Ratio | 7.387 |
| Quick Ratio | 7.387 |
| Cash Ratio | 7.379 |
RGC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -50.504 |
| Return on Equity | -54.809 |
| Return on Total Capital | -66.317 |
| Return on Invested Capital | -53.75 |
RGC Capital Structure
| Total Debt to Total Equity | 11.201 |
| Total Debt to Total Capital | 10.073 |
| Total Debt to Total Assets | 9.459 |
| Long-Term Debt to Equity | 4.766 |
| Long-Term Debt to Total Capital | 4.286 |